MiNK Therapeutics（INKT）股价在盘前交易中暴跌23.7%，跌至每股31美元，公司宣布了一项股权融资计划。这家总部位于纽约的企业提交了高达5000万美元的市场股权销售（ATM）方案，由B. Riley Securities负责执行。资金将用于营运资本及其他一般性开支，包括研发支出、临床前和临床开发，以及候选产品的商业化推进。
背景回顾：上周五，公司股价曾飙升730%，收盘报64.17美元，因旗下实验性同种异体细胞疗法agenT-797在晚期睾丸癌患者中实现完全缓解，相关成果已发表在《Oncogene》期刊。中期数据预计在未来数月公布，研究仍在招募患者中。然而，本周一股价回落约37%，收于40.61美元。
公司基本面：截至周一，MiNK Therapeutics市值约1.62亿美元，流通股约400万股，公众流通股约100万股。分析师评级方面，两家券商给予“买入”评级，一家建议“持有”；目标价分别为B. Riley的7美元和H.C. Wainwright的35美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.